10-Q/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 10-Q/A

☒QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15 (d) OF THE

SECURITIES EXCHANGE ACT OF 1934

 For the quarterly period ended: March 31, 2021

Commission file number: 0-21271

SANGUI BIOTECH INTERNATIONAL, INC.

(Exact name of registrant as specified in its charter)

Colorado (CO)	84-1330732
(State or other jurisdiction of incorporation or organization)	(I.R.S. Employer Identification No.)

Bleichenbrücke 9, 20354 Hamburg, Germany

(Address of principal executive offices)

011-49-40-46093120

(Registrant's telephone number, including area code)

 Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading Symbol	Name of exchange on which registered
None	N/A	N/A

Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. 

Yes [X]       No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).

Yes [X]       No [   ]

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company.  See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer   [  ]	Accelerated Filer   [  ]
Non-Accelerated Filer   [X]	Smaller Reporting Company   ☒
Emerging Growth Company   ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).   

Yes ☐       No [X]

As of May 7, 2021, there were 206,955,598 shares of the issuer's Common Stock, no par value, issued and 206,901,842 shares outstanding.

EXPLANATORY NOTE

The purpose of this Amendment No. 1 to the Periodic Report of Sangui Biotech International, Inc. (the “Company”) on Form 10-Q for the fiscal period ended March 31, 2021, filed with the Securities and Exchange Commission on May 7, 2021 (the “Form 10-Q”) is to correct the information in Part II Item 2. The Company in its Form 10-Q filing indicated that there had been no unregistered sales of its equity securities, while in fact there had been a sale of stock subsequent to the period covered by the report. This Amendment No. 1 corrects this section to reflect the recent issuance. No changes are hereby made to the registrant’s financial statements.

SANGUI BIOTECH INTERNATIONAL, INC.

Quarterly Report on Form 10-Q

For the Quarterly Period Ended March 31, 2021

INDEX

PART I – FINANCIAL INFORMATION
Item 1	Financial Statements	1
Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12
Item 3.	Quantitative and Qualitative Disclosure About Market Risk	16
Item 4.	Controls and Procedures	16
PART II – OTHER INFORMATION
Item 1.	Legal Proceedings	17
Item 1A.	Risk Factors	17
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	17
Item 3.	Defaults Upon Senior Securities	17
Item 5.	Other Information	17
Item 6.	Exhibits	17

ii

PART I - FINANCIAL INFORMATION

Item 1 - Financial Statements

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with the instructions to Form 10-Q pursuant to the rules and regulations of the Securities and Exchange Commission and, therefore, do not include all information and footnotes necessary for a complete presentation of our financial position, results of operations, cash flows, and stockholders' deficit in conformity with generally accepted accounting principles in the United States of America. In the opinion of management, all adjustments considered necessary for a fair presentation of the consolidated results of operations and financial position have been included and all such adjustments are of a normal recurring nature.

Our unaudited condensed consolidated balance sheet as of March 31, 2021 and the audited consolidated balance sheet as of June 30, 2020, our unaudited condensed consolidated statements of operations and comprehensive loss for the three- and nine-month period ended March 31, 2021, and 2020, our unaudited condensed consolidated statements of stockholders’ deficit for the three- and nine-month periods ended March 31, 2021, and 2020 and our unaudited condensed consolidated statements of cash flows for the nine-month period ended March 31, 2021, and 2020 are attached hereto.

1

SANGUI BIOTECH INTERNATIONAL, INC.
Consolidated Balance Sheets
			March 31,		June 30,
			2021		2020
				(unaudited)
ASSETS
CURRENT ASSETS
	Cash		$	11,620	$	15,282
	Prepaid expenses and other assets			14,995		13,361
	Tax refunds receivable			737		3,317
	Accounts receivable, net			25,152		9,858
	Note receivable, related party			2,066		6,878
		Total Current Assets		54,570		48,696
	Property and Equipment, Net			1,405		1,922
	Operating lease right-of-use asset			70,349		74,710
		TOTAL ASSETS	$	126,324	$	125,328
LIABILITIES AND STOCKHOLDERS' DEFICIT
LIABILITIES
	Accounts payable and accrued expenses		$	135,140	$	119,246
	Accrued interest  - related party			57,343		42,359
	Notes payable - related party			745,962		618,568
	Current portion of operating lease liability			13,743		11,312
		Total Current Liabilities		952,188		791,485
	Operating lease liability, net of current portion			57,390		63,721
		Total  Liabilities		1,009,578		855,206
STOCKHOLDERS' DEFICIT
	Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding		$	-	$	-
	Common stock, no par value; 250,000,000 shares authorized 203,355,598 and 203,355,598 shares issued and 203,301,842 and 203,301,842 shares outstanding respectively			33,027,676		33,027,676
	Additional paid-in capital			4,513,328		4,513,328
	Treasury stock, at cost			(19,387)		(19,387)
	Accumulated other comprehensive income			90,454		91,907
	Accumulated deficit			(37,845,291)		(37,696,425)
	Total Sangui Biotech International, Inc's stockholders' defict			(233,220)		(82,901)
	Non-controlling interest			(650,034)		(646,977)
		Total Stockholders' Deficit		(883,254)		(729,878)
		TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$	126,324	$	125,328
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

2

SANGUI BIOTECH INTERNATIONAL, INC.
Condensed Consolidated Statements of Operations and Comprehensive Loss
(unaudited)
		For the Three Months Ended				For the Nine Months Ended
		March 31,				March 31,
		2021		2020		2021		2020
REVENUES
	License revenues	$	21,182	$	9,211	$	51,754	$	21,176
GROSS MARGIN			21,182		9,211		51,754		21,176
OPERATING EXPENSES
	Research and development		2,060		1,535		6,482		6,421
	Professional fees		32,911		35,521		117,750		114,939
	General and administrative		14,330		8,590		37,951		28,682
	Depreciation and amortization		206		1,020		610		1,020
Total Operating Expenses			49,507		46,666		162,793		151,062
OPERATING LOSS			(28,325)		(37,455)		(111,039)		(129,886)
OTHER INCOME (EXPENSE)
	Loss on out of court settlement		-		-		-		(6,714)
	Gain (Loss) on foreign exchange		32,167		12,838		(27,611)		19,547
	Interest expense		(4,580)		(3,667)		(13,273)		(10,357)
Total other income (expense)			27,587		9,171		(40,884)		2,476
LOSS BEFORE INCOME TAXES AND NON-CONTROLLING INTEREST			(738)		(28,284)		(151,923)		(127,410)
	Provision for income taxes		-		-		-		-
NET LOSS BEFORE NON-CONTROLLING INTEREST			(738)		(28,284)		(151,923)		(127,410)
	Less: Net loss attributable to non-controlling interest		648		1,588		3,057		3,982
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS		$	(90)	$	(26,696)	$	(148,866)	$	(123,428)
OTHER COMPREHENSIVE LOSS
	Foreign currency translation adjustments		(287)		(1,894)		(1,453)		(1,129)
COMPREHENSIVE LOSS		$	(1,025)	$	(30,178)	$	(153,376)	$	(128,539)
	BASIC AND DILUTED LOSS PER SHARE	$	(0.00)	$	(0.00)	$	(0.00)	$	(0.00)
	BASIC AND DILUTED WEIGHTED AVERAGE
	NUMBER OF SHARES OUTSTANDING		203,355,598		202,308,054		203,355,598		201,313,316
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

3

SANGUI BIOTECH INTERNATIONAL, INC.
Condensed Consolidated Statements of Stockholders' Deficit
(unaudited)
	Three-Month Period Ended March 31, 2021
								Accumulated
				Additional				Other		Non-
	Common Stock			Paid-In		Treasury		Comprehensive		controlling		Accumulated
	Shares	Amount		Capital		Stock		Income (Loss)		Interest		Deficit		Total
Balance, January 1, 2021	203,355,598	$	33,027,676	$	4,513,328	$	(19,387)	$	90,741	$	(649,386)	$	(37,845,201)	$	(882,229)
Currency translation adjustment	-		-		-		-		(287)		-		-		(287)
Net loss	-		-		-		-		-		(648)		(90)		(738)
Balance, March 31, 2021	203,355,598	$	33,027,676	$	4,513,328	$	(19,387)	$	90,454	$	(650,034)	$	(37,845,291)		(883,254)
SANGUI BIOTECH INTERNATIONAL, INC.
Condensed Consolidated Statements of Stockholders' Deficit
(unaudited)
	Nine-Month Period Ended March 31, 2021
								Accumulated
				Additional				Other		Non-
	Common Stock			Paid-In		Treasury		Comprehensive		controlling		Accumulated
	Shares	Amount		Capital		Stock		Income		Interest		Deficit		Total
Balance, July 1, 2020	203,355,598	$	33,027,676	$	4,513,328	$	(19,387)	$	91,907	$	(646,977)	$	(37,696,425)	$	(729,878)
Currency translation adjustment	-		-		-		-		(1,453)		-		-		(1,453)
Net loss	-		-		-		-		-		(3,057)		(148,866)		(151,923)
Balance, March 31, 2021	203,355,598	$	33,027,676	$	4,513,328	$	(19,387)	$	90,454	$	(650,034)	$	(37,845,291)		(883,254)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

4

SANGUI BIOTECH INTERNATIONAL, INC.
Condensed Consolidated Statements of Stockholders' Deficit
(unaudited)
	Three-Month Period Ended March 31, 2020
								Accumulated
				Additional				Other		Non-
	Common Stock			Paid-In		Treasury		Comprehensive		controlling		Accumulated
	Shares	Amount		Capital		Stock		Income (Loss)		Interest		Deficit		Total
Balance, January 1, 2020	201,533,598	$	33,012,261	$	4,513,328	$	(19,387)	$	92,212	$	(643,586)	$	(37,600,416)		(645,588)
Common shares issued for Cash	1,250,000		11,055		-		-		-		-		-		11,055
Common stock issued out of court settlement	-		-		-		-		-		-		-		-
Currency translation adjustment	-		-		-		-		(1,894)		-		-		(1,894)
Net loss	-		-		-		-		-		(1,588)		(26,696)		(28,284)
Balance, March 31, 2020	202,783,598	$	33,023,316	$	4,513,328	$	(19,387)	$	90,318	$	(645,174)	$	(37,627,112)	$	(664,711)
SANGUI BIOTECH INTERNATIONAL, INC.
Condensed Consolidated Statements of Stockholders' Deficit
(unaudited)
	Nine-Month Period Ended March 31, 2020
								Accumulated
				Additional				Other		Non-
	Common Stock			Paid-In		Treasury		Comprehensive		controlling		Accumulated
	Shares	Amount		Capital		Stock		Income		Interest		Deficit		Total
Balance, July 1, 2019	199,295,503	$	32,967,499	$	4,513,328	$	(19,387)	$	91,447	$	(641,192)	$	(37,503,684)		(591,989)
Common stock issued for cash	1,250,000		11,055		-		-		-		-		-		11,055
Common stock issued for services	2,238,095		44,762		-		-		-		-		-		44,762
Currency translation adjustment	-		-		-		-		(1,129)		-		-		(1,129)
Net loss	-		-		-		-		-		(3,982)		(123,428)		(127,410)
Balance, March 31, 2020	202,783,598	$	33,023,316	$	4,513,328	$	(19,387)	$	90,318	$	(645,174)	$	(37,627,112)	$	(664,711)
The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

5

SANGUI BIOTECH INTERNATIONAL, INC.
Condensed Consolidated Statements of Cash Flows
(unaudited)
				For the Nine Months Ended
				March 31,
				2021		2020
CASH FLOWS FROM OPERATING ACTIVITIES
	Net loss			$	(151,923)	$	(127,410)
	Adjustments to reconcile net loss to net cash
	used by operating activities:
		Depreciation and amortization			610		1,020
		Common stock issued for out of court settlement			-		6,714
		Foreign currency exchange transactions			27,611		(19,495)
		Amortization of Right-of-use asset			(16,009)		(7,898)
	Changes in operating assets and liabilities
		Trade accounts receivable			(15,518)		17,261
		Prepaid expenses and other current assets			(5,193)		(3,387)
		Tax refunds receivable			6,660		(6,021)
		Accounts payable and accrued expenses			15,604		(9,091)
		Related party advances			5,665		2,054
		Related party accounts payable			11,852		10,202
		Operating lease liability			16,463		7,898
			Net Cash Used in Operating Activities		(104,178)		(128,153)
CASH FLOWS FROM INVESTING ACTIVITIES
		Purchase of equipment			-		(3,102)
			Net Cash Used in Investing Activities		-		(3,102)
CASH FLOWS FROM FINANCING ACTIVITIES
		Proceeds from related party note payable			101,515		105,222
		Proceeds from common stock issued for cash			-		11,055
			Net Cash Provided by Financing Activities		101,515		116,277
EFFECTS OF EXCHANGE RATES ON CASH					(999)		(907)
	NET CHANGES IN CASH				(3,662)		(15,885)
	CASH AT BEGINNING OF PERIOD				15,282		27,453
	CASH AT END OF PERIOD			$	11,620	$	11,568
	CASH FLOW INFORMATION
	NON - CASH INVESTING AND FINANCING ACTIVITIES
		Right-of-use operating lease assets obtained in exchange for lease liabilities		$	-	$	81,936
		Common Stock issued in settlement of liability		$	-	$	44,762
	The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.

6

SANGUI BIOTECH INTERNATIONAL, INC.

Notes to the Condensed Consolidated Financial Statements

March 31, 2021 and June 30, 2020

(Unaudited)

NOTE 1 - BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America and rules of the Securities Exchange Commission for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2020. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the three- and nine-month period ended March 31, 2021 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2021.

In December 2019, COVID-19 emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders and advisories and quarantining of people who may have been exposed to the virus. At the present time, it is not clear how long this crisis will last and what extent it will take. The highest priority for the Company is the health of employees and business partners. The Company’s main product is affected by the restrictions currently in place around the world. The global restrictions drastically limit our sales activities. Therefore, the license revenue the Company anticipated is not, and for the foreseeable future, will not be received at the levels as planned. The Company is in close contact with its licensee who is responsible for all distribution. Both the Company and its licensee assume that the desired growth of sales will be resumed after the pandemic has been overcome and restrictions are lessened. Prior to the pandemic, the Company had essentially been financed through the sale of shares or by loans from related parties. These financing options are still available to the Company during the COVID-19 crisis.

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

Sangui Biotech International, Inc., (Sangui or the Company) was incorporated in Colorado in 1995 and conducts business through its 90% owned subsidiary, Sangui BioTech GmbH (Sangui GmbH) and its 99.8% owned subsidiary Sangui Know-how und Patentverwertungsgesellschaft mbH & Co. KG (Sangui KG). Sangui GmbH, which is headquartered in Hamburg, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Sangui KG is a limited partnership that holds the license rights under the various agreements that the Company enters into from time to time.

Consolidation

The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Foreign Currency Translation

Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period.

Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2021 and June 30, 2020 and our unaudited consolidated statements of operations for the three- month periods ended March 31, 2021 and 2020, were calculated as follows:

7

SANGUI BIOTECH INTERNATIONAL, INC.

Notes to the Condensed Consolidated Financial Statements

March 31, 2021 and June 30, 2020

(Unaudited)

as of March 31, 2021	0.851250
as of March 31, 2020	0.911235
July 1, 2020 through March 31, 2021	0.841351
July 1, 2019 through March 31, 2020	0.902936

The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other Income.

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,845,291 as of March 31, 2021. The Company incurred a net loss before non-controlling interest of $151,923 for the nine-months ended March 31, 2021 and used cash in operating activities of $104,178 during the same nine-months ended March 31, 2021. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Cash and Cash Equivalents

The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts.

Research and Development

Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred.

Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

8

SANGUI BIOTECH INTERNATIONAL, INC.

Notes to the Condensed Consolidated Financial Statements

March 31, 2021 and June 30, 2020

(Unaudited)

Type of Revenue

The Company derives revenue primarily from licensing fees on sales of its wound spray product.

The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below.

The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied.

Basic and Diluted Earnings (Loss) Per Common Share

Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2021, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive.

Comprehensive Loss

Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit).

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity.

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

9

SANGUI BIOTECH INTERNATIONAL, INC.

Notes to the Condensed Consolidated Financial Statements

March 31, 2021 and June 30, 2020

(Unaudited)

NOTE 3 - COMMITMENTS AND CONTINGENCIES

Litigation

The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a

material effect on the Company's financial position or results of operations.

At the time of reporting, no litigation is pending.

Indemnities and Guarantees

During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet.

Leases

The Company leases office facilities from an unrelated third party at 1,110 Euros per month, which amount includes 177 Euros for sales tax. The office lease contract began in January 2020 and expires June 2026. The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month that began June 2018 expired May 2020.  The company has extended the expired contract until May 2021. The monthly leasing rate is 670 Euros for the period from June 2020 to May 2021.

The following table reconciles future minimum operating lease payments to the discounted lease liability as of March 31, 2021:

Minimum Lease Payments Under Operating Leases
		Office		Automotive		Total
Year ending June 30,
2021	$	3,351	$	1,573	$	4,924
2022		13,514		-		13,514
2023		13,758		-		13,758
2024		14,005		-		14,005
Thereafter		28,772		-		28,772
Total Operating Lease Obligations	$	73,400	$	1,573	$	74,973
Less: Amount representing imputed interest	$	(3,836)	$	(4)	$	(3,840)
Present Value of minimum lease payments	$	69,564	$	1,569	$	71,133
Weighted average discount rate		2%
Weighted average remaining term		5.14	years

License Agreement

Pursuant to the contracts dated May 2, 2018 and November 11, 2018 between Sangui GmbH and Sangui KG, respectively, and a former contractor, Sangui KG grants that contractor a license fee on the license income received by Sangui for his previous services as a co-inventor. The license fee is 10% analogously to the remuneration regulation of the German Law on Employee Inventions (ArbnErfG).

10

SANGUI BIOTECH INTERNATIONAL, INC.

Notes to the Condensed Consolidated Financial Statements

March 31, 2021 and June 30, 2020

(Unaudited)

NOTE 4 – DEBT

Notes Payable Related Parties

As of March 31, 2021, the Company had outstanding the following loans payable due to a Company Director:

Date	Loan amount in EURO	Loan amount converted into USD	Interest rate	Interest  in USD	Due
March 06, 2015	100,000	117,474	5%	34,625	June 30, 2020
December 12, 2017	25,000	29,369	2%	1,939	on demand
January 19, 2018	25,000	29,369	2%	1,878	on demand
March 13, 2018	25,000	29,369	2%	1,793	on demand
July 16, 2018	25,000	29,369	2%	1,592	on demand
September 10, 2018	25,000	29,369	2%	1,501	on demand
October 04, 2018	25,000	29,369	2%	1,463	on demand
December 27, 2018	25,000	29,369	2%	1,328	on demand
January 21, 2019	15,000	17,621	2%	772	on demand
February 26, 2019	25,000	29,369	2%	1,229	on demand
March 20, 2019	25,000	29,369	2%	1,194	on demand
April 08, 2019	20,000	23,495	2%	931	on demand
May 09, 2019	30,000	35,242	2%	1,336	on demand
June 21, 2019	30,000	35,242	2%	1,253	on demand
September 17, 2019	20,000	23,495	2%	722	on demand
October 04, 2019	20,000	23,495	2%	700	on demand
October 30, 2019	20,000	23,495	2%	667	on demand
January 08, 2020	10,000	11,747	2%	288	on demand
February 20, 2020	10,000	11,747	2%	261	on demand
March 06, 2020	15,000	17,621	2%	377	on demand
April 01, 2020	10,000	11,747	2%	234	on demand
May 05, 2020	15,000	17,621	2%	319	on demand
June 10, 2020	10,000	11,747	2%	189	on demand
July 27, 2020	10,000	11,747	2%	159	on demand
September 07, 2020	10,000	11,747	2%	132	on demand
September 21, 2020	10,000	11,747	2%	123	on demand
October 09, 2020	15,000	17,621	2%	167	on demand
December 03, 2020	10,000	11,747	2%	76	on demand
January 05, 2021	10,000	11,747	2%	55	on demand
Februay 11, 2021	10,000	11,747	2%	31	on demand
March 17, 2021	10,000	11,747	2%	9	on demand
Total	635,000	745,962		57,343

On July 27, 2020, September 07, 2020, September 21, 2020, October 09,2020, December 03,2020, January 05, 2021, February 11, 2021 and on March 17, 2021 a Company Director advanced amounts totaling 85,000 Euros ($101,515 as of March 31, 2021) to the Company. The loans are due on demand, accrue interest annually at 2% and are unsecured.    

As of March 31, 2021, all notes issued have total interest accrued of $57,343.

Interest expense for the nine-month period ended March 31, 2021 and 2020 was $13,273 and $10,357, respectively.

11

SANGUI BIOTECH INTERNATIONAL, INC.

Notes to the Condensed Consolidated Financial Statements

March 31, 2021 and June 30, 2020

(Unaudited)

NOTE 5 – STOCKHOLDERS’ DEFICT

Preferred Stock – The Company is authorized to issue 10,000,000 shares of preferred stock. No preferred stock has been issued to date. The authorized preferred shares are non-voting and the Board of Directors has not designated any liquidation value or dividend rates.

Common Stock – The Company is authorized to issue 250,000,000 shares of no - par value common stock. The holders of the Company's common stock are entitled to one vote for each share held of record on all matters to be voted on by those stockholders. As of March 31, 2021, and June 30, 2020, the Company had 203,355,598 and 203,355,598 shares of common stock issued and 203,301,842 and 203,301,842 shares outstanding, respectively.

Treasury Stock - The Company holds 53,756 of its common stock as treasury stock, which is valued at cost of $19,387 as of March 31, 2021.

NOTE 6 – SUBSEQUENT EVENTS

Subsequent to March 31, 2021, the Company sold 3,600,000 shares of its common stock for approximately $58,737 in cash proceeds to one individual at price of approximately $0.0163 per share.

In accordance with ASC 855-10, the Company’s management has reviewed all material events and there are no additional material subsequent events to report.

12

Item 2 - Management's Discussion and Analysis of Financial Condition and Results of Operations

Forward-looking Statements

The following discussion of our financial condition and results of operations should be read in conjunction with the consolidated financial statements and the related notes thereto included elsewhere in this quarterly report. Some of the information in this quarterly report contains forward-looking statements, including statements related to anticipated operating results, margins, growth, financial resources, capital requirements, adequacy of the Company's financial resources, trends in spending on research and development, the development of new markets, the development, regulatory approval, manufacture, distribution, and commercial acceptance of new products, and future product development efforts. Investors are cautioned that forward-looking statements involve risks and uncertainties, which may affect our business and prospects, including but not limited to, the Company's expected need for additional funding and the uncertainty of receiving the additional funding, changes in economic and market conditions, acceptance of our products by the health care and reimbursement communities, new development of competitive products and treatments, administrative and regulatory approval and related considerations, health care legislation and regulation, and other factors discussed in our filings with the Securities and Exchange Commission.

GENERAL

Our mission is the development of novel and proprietary pharmaceutical, medical and cosmetic products. We develop our products through our German subsidiary, Sangui GmbH. Currently, we are seeking to market and sell our products through partnerships with industry partners worldwide.

Our focus has been the development of oxygen carriers capable of providing oxygen transport in humans in the event of acute and/or chronic lack of oxygen due to arterial occlusion, anemia or blood loss whether due to surgery, trauma, or other causes, as well as in the case of chronic wounds. We have thus far focused our development and commercialization efforts on such artificial oxygen carriers by reproducing and synthesizing polymers out of native hemoglobin of defined molecular sizes. In addition, we have developed external applications of oxygen transporters in the medical and cosmetic fields in the form of sprays for the healing of chronic wounds and of gels and emulsions for the regeneration of the skin. A wound dressing that shows outstanding properties in the support of wound healing, is being distributed by SastoMed GmbH (Sastomed), a former joint venture company in which we had held a share of 25%, as global licensee under the Granulox brand name. Effective as of the end of the second quarter of our fiscal year 2016 we sold this stake to SanderStrohmann GmbH.

Sangui GmbH holds distribution rights for our Chitoskin wound pads for the European Union and various other countries. Additionally, a European patent has been granted for the production and use of improved Chitoskin wound pads.

Our current key business focuses are: (a) selling our existing cosmetics and wound management products by way of licensing through distribution partners, or by way of direct sale, to end users; (b) identifying additional industrial and distribution partners for our patents, production techniques, and products; and (c) obtaining the additional certifications on our products in development.

Artificial Oxygen Carriers

Sangui GmbH develops several products based on polymers of purified natural porcine hemoglobin with oxygen carrying abilities that are similar to native hemoglobin. These are (1) oxygen carrying blood additives and (2) oxygen carrying blood volume substitutes.

According to regulatory requirements, all drugs must complete preclinical and clinical trials before approval (e.g. Federal Drug Administration approval) and market launch. The Company’s management believes that the European and FDA approval process will take at a minimum several years to complete.

Our most promising potential product in the area of artificial oxygen carriers, the blood additive, is still in an early development stage. In the pursuit of these projects, we will need to obtain substantial additional capital to

13

continue their development. As the Company has limited financial resources, we have suspended this project temporarily in order to focus our attention on our chronic wound research and the products developed in conjunction with their treatment.

Nano Formulations for the Regeneration of the Skin

Healthy skin is supplied with oxygen both from the inside as well as through diffusion from the outside. A lack of oxygen will cause degenerative alterations, ranging from premature aging, to surface damage, and even as extensive as causing open wounds. The cause for the lack of oxygen may be a part of the normal aging process, but it may also be caused by burns, radiation, trauma, or a medical condition. Impairment of the blood flow, for example caused by diabetes mellitus or by chronic venous insufficiency, can also lead to insufficient oxygen supply and the resulting skin damage.

In response, we developed nano-emulsion based cosmetic preparations that in their design are able to help support regeneration of the skin by improving its oxygen supply. Our line of cosmetic products was thoroughly tested by an independent research institute and received top marks for skin moisturizing, and enhanced skin elasticity, respectively. However, sales of this series remained at low levels and during the first quarter of the 2016 financial year we decided to decrease our operations in this particular segment and to abandon the patent protection for this range of products.

Chitoskin Wound Pads

Usually, normal (“primary”) wounds tend to heal over a couple of days without leaving scars following a certain sequence of phases. Burns and certain diseases impede the normal wound healing process, resulting in large, hardly healing (“secondary”) wounds which only close by growing new tissue from the bottom. Wound dressings serve to safeguard the wound with its highly sensitive new granulation tissue from mechanical damage as well as from infection. Using the natural polymer chitosan, Sangui’s Chitoskin wound dressings show outstanding properties in supporting wound healing. Sangui GmbH holds various distribution rights for our Chitoskin wound pads, and it is the strategy of the company to find industry partners ready to acquire or license this product range as a whole.

Hemospray Wound Spray

Sangui GmbH has developed a novel medical technology supporting the healing of chronic wounds. Lack of oxygen supply to the cells in the wound ground is the main reason why those wounds lose their genuine healing power. Based on its concept of artificial oxygen carriers, the wound spray product we developed bridges the watery wound surface and permits an enhanced afflux of oxygen to the wound ground.

Sangui GmbH has granted SastoMed global distribution rights to this product. Distribution of the wound spray began in the European Union in April 2012 under the brand name “Granulox.”

In December 2012, product distribution was initiated in Mexico by Sastomed and their local distribution partner Bio-Mac Pharma. International distribution has been expanded since then through cooperation agreements with local distribution partners in the Benelux countries and South Eastern Europe.

Since December 2013, international distribution outside Germany in collaboration with local partners has occurred in more than 40 countries in Europe and Latin American.

On November 13, 2017, the Company announced that Infirst Healthcare Ltd has announced that the United States (US) Food and Drug Administration had granted Fast Track designation to Granulox for the treatment of diabetic foot ulcers. It is the first and only hemoglobin spray to receive the Fast-Track designation - a process designed to facilitate the development, and expedite the review of, new therapies to treat serious conditions and fill an unmet medical need.

14

Despite the positive reviews of our product, Granulox sales have become more volatile.  We remain confident, however, that SastoMed will be able to considerably increase its sales in conjunction with increased distribution of the product into more international markets.

In December 2010, Sangui GmbH established a joint venture company with SanderStrothmann GmbH of Georgsmarienhuette, Germany, under the name of SastoMed GmbH. This enterprise was in charge of obtaining the CE mark certification authorizing the distribution of one of SGBI’s products in the member states of the European Union. Effective December 31, 2015, Sangui GmbH sold its stake in Sastomed GmbH to SanderStrohmann GmbH.

On or about June 18, 2018, Sangui GmbH together with Sastomed GmbH founded Sangui Know-How- und Patentverwertungsgesellschaft mbH & Co. KG (“Sangui KG”). Sangui KG is a limited partnership. On June 22, 2018, Sangui KG acquired all the rights in the license agreement made on December 17, 2010, between Sastomed GmbH and Sangui GmbH.

Pursuant to the contracts dated May 2, 2018 and November 11, 2018 between Sangui GmbH and Sangui KG, respectively, and a former contractor Sangui KG grants that contractor a license fee on the license income received by Sangui for his previous services as a co-inventor. The license fee is 10% analogously to the remuneration regulation of the German Law on Employee Inventions (ArbnErfG).

Given the Company’s business strength is primarily in research and product development, we have decided to partner with established distribution entities who license our marketable products, or those products that are close to market entry, for sale to end users. In pursuit of this strategy, we have licensed the most promising product, a hemoglobin based wound spray technology to Sastomed GmbH, a former joint venture of SGBI, for distribution in several European, Latin American and Asian countries. In addition, we are entering the preclinical testing of hemoglobin based artificial oxygen carriers aiming at the remediation of ischemic conditions in human patients.

Effective July 27, 2020, Sastomed GmbH was merged with its parent company Mölnlycke Health Care GmbH, Düsseldorf. As a result of the merger, the license agreement between Sastomed GmbH and Sangui Know-How und Patentverwertungsgesellschaft mbH & Co. KG is transferred with all rights and obligations to the receiving Mölnlycke Health Care GmbH.

FINANCIAL POSITION

During the nine-months ended March 31, 2021, our total assets increased $996 from $125,328 on June 30, 2020 to $126,324 on March 31, 2021. An increase of accounts receivable of $15,294 partially offset by a decrease of operating lease right-of-use assets of $ 4,361 and a decrease of cash of $ 3,662 from June 30, 2020 to March 31, 2021 were primarily responsible for the increase in the total assets.

We funded our operations primarily through our existing cash reserves and cash received from the issuance notes payables from related parties. Our stockholders’ deficit increased by $153,376 from ($ 729,878) on June 30, 2020 to ($883,254) on March 31, 2021. The primary factor behind this was net loss attributable to common stockholders of $148,866.

RESULTS OF OPERATIONS

For the three-month and nine-month period March 31, 2021 and 2020:

REVENUES – Revenues reported were $ 21,182 and $ 9,211 for the three-months ended March 31, 2021 and 2020 respectively. For the nine-months ended March 31, 2021 and 2020 revenues were $51,754 and $21,176.  The increase of $11,971 and the increase of $30,578 can be traced back to the development in royalties from the licensing agreement with Mölnlycke Heath Care GmbH.

RESEARCH AND DEVELOPMENT– Research and development expenses increased by $ 525 to $ 2,060 from $1,535 for the three-month periods ending March 31, 2021 and 2020. Research and development expenses

15

increased $61 to $6,482 in the nine months of our 2021financial year from $6,421 in the comparable period of the previous year. This increase mainly attributed to higher fees for patents.

GENERAL AND ADMINISTRATIVE and PROFESSIONAL FEES – The combined accumulated general and administrative expenses and professional fees increased $3,130 to $47,241 during the three-months ended March 31, 2021, from $44,111 in the respective period of the previous year mainly due to higher of costs for cars and license expenses offset by lower costs for legal advice. Accumulated general and administrative expenses and professional fees increased $12,080 to $155,701 in the nine months ended March 31, 2021, from $143,621 in the respective period of the previous year mainly due to higher of costs for tax advice, cars, rent and license expenses.

DEPRECIATION AND AMORTIZATION - Depreciation and amortization were $206 and $1,020 for the three-months and $610 and $1,020 for the nine-months ended March 31, 2021 and 2020 respectively.

GAIN/LOSS ON FOREIGN EXCHANGE – The three-month period ended March 31, 2021 shows gains on foreign exchange of $ 32,167 compared to gains of $12,838 during the respective period of the previous year, hence a change of $19,329. The nine-month period ended March 31, 2021 shows losses on foreign exchange of $27,611 compared to gains of $19,547 during the respective period of the previous year, hence a change of $47,158. The change is mainly due to the revaluation of notes payables denominated in Euros at the end of each period.

INTEREST EXPENSE - Interest expenses for the three-month period ended March 31, 2021 and 2020 increased by $913 to $4,580 from $3,667. For the nine-months ended March 31, 2021 and 2020, interest expense increased by $2,916 to $13,273 from $10,357. The increase relates to the increase of interest - bearing debt financing.   

NET LOSS - As a result of the above factors, the net loss attributed to common shareholders decreased to $90 compared to a loss of $ 26,696 for the three-months ended March 31, 2021 and 2020 and increased $25,438 to $148,866 compared to a loss of $123,428 for the nine-months ended March 31, 2021 and 2020 respectively. The loss per share for both periods was $(0.00).

Our consolidated net loss before non-controlling interest was $738 or $(0.00) per common share, for the three-months ended March 31, 2021, compared to $28,284 or $(0.00) per common share, during the comparable period in our 2020 financial year. Our consolidated net loss before non-controlling interest was $151,923 or $(0.00) per common share, for the nine-months ended March 31, 2021, compared to $127,410 or $(0.00) per common share, during the comparable period in our 2020 financial year.

LIQUIDITY AND CAPITAL RESOURCES

For the nine-months ended March 31, 2021, net cash used in operating activities increased $23,975 to ($104,178), compared to ($128,153) in the corresponding period of the previous year. This is mainly due to an increase accounts payables and accrued expenses of $ 15,604 and related party payables of $11,852.

The Company funded its business in the first nine-months ended March 31, 2021 by issuing note payables totaling Euros 85,000 ($101,515).

We had a working capital deficit of approximately $897,618 on March 31, 2021an increase of approximately $154,829 from June 30, 2020.  

On March 31, 2021 compared to June 30, 2020, we had cash of $11,620 compared to $15,282, prepaid expenses of $14,995 compared to $13,361 and accounts receivable of $25,152 compared $9,858. We will need substantial additional funding to fulfill our business plan and we intend to explore financing sources for our future development activities.  No assurance can be given that these efforts will be successful.

16

Item 3 - Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by §229.10(f)(1) and are not required to provide the information under this item.

Item 4 - Controls and Procedures

Disclosure Controls and Procedures

As of the date of the end of the period covered by this report, our Chief Executive Officer and Chief Financial Officer conducted an evaluation of the effectiveness of the design and operation of our disclosure controls and procedures, as required by Exchange Act Rule 13a-15. Based on that evaluation, our Chief Executive Officer and Chief Financial Officer concluded that our disclosure controls and procedures were not effective as of the end of the period covered by this report to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified by the SEC’s rules and forms. 

Disclosure controls and procedures are controls and other procedures that are designed to ensure that information required to be disclosed in our reports filed or submitted under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC’s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed in our reports filed under the Exchange Act is accumulated and communicated to management, including our Chief Executive Officer and our Chief Financial Officer, to allow timely decisions regarding required disclosure. 

Changes in Internal Control Over Financial Reporting

There has been no change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. 

The term “internal control over financial reporting” is defined as a process designed by, or under the supervision of, the registrant’s principal executive and principal financial officers, or persons performing similar functions, and effected by the registrant’s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that: 

(a)Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the registrant; 

(b)Provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the registrant are being made only in accordance with authorizations of management and directors of the registrant; and 

(c)Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the registrant’s assets that could have a material effect on the financial statements. 

17

PART II - OTHER INFORMATION

Item 1 - Legal Proceedings

The Company is not aware of pending claims or assessments, which may have a material adverse impact on the Company’s financial position or results of operations. 

Item 1a - Risk Factors

We are a smaller reporting company as defined by §229,10(f)(1) and are not required to provide the information under this item. 

Item 2 - Unregistered Sales of Equity Securities and Use Of Proceeds

Subsequent to the period covered by this report, the Company sold 3,600,000 shares of its common stock for approximately $58,737 to one individual, at price of approximately $0.0163 per share. No underwriters were used. The securities were sold pursuant to an exemption from registration provided by Regulation S and Section 4(2) of the Securities Act of 1933. The certificate representing the shares contained a restricted legend.

Item 3 - Defaults Upon Senior Securities

None.

Item 5 - Other Information

None.  

Item 6 – Exhibits

1.           Financial Statements.  The unaudited condensed consolidated Balance Sheet of Sangui Biotech International, Inc. as of March 31, 2021 and the audited balance sheet as of June 30, 2020, the unaudited condensed consolidated Statements of Operations for the nine - month periods ended March 31, 2021 and 2020, the unaudited condensed consolidated Statements of Stockholder’s Deficit as of March 31,  2021 and 2020, and the unaudited condensed consolidated Statements of Cash Flows for the nine-month period ended March 31, 2021 and 2020, together with the notes thereto, are included in this Quarterly Report on Form 10-Q.

2.           Exhibits. The following exhibits are either filed as a part hereof or are incorporated by reference. Exhibit numbers correspond to the numbering system in Item 601 of Regulation S-K.

Exhibit       

Number     Description of Exhibit

31.01	Certification of CEO Pursuant to Rule 13a-14(a) and 15d-14(a), filed herewith
31.02	Certification of principal financial officer Pursuant to Rule 13a-14(a) and 15d-14(a), filed herewith
32.01	Certification Pursuant to Section 1350 of Title 18 of the United States Code, filed herewith

18

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

SANGUI BIOTECH INTERNATIONAL, INC.

Dated: May 7, 2021/s/ Thomas Striepe                                               

By: Thomas Striepe 

Chief Executive Officer and Principal Financial Officer 

19

EX-31.1

Exhibit 31.01

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO RULE 13a-14

I, Thomas Striepe, certify that:

1. I have reviewed this quarterly report on Form 10-Q of Sangui Biotech International, Inc.;

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have, for the small business issuer and have:

(a)         Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in  accordance with generally accepted accounting principles; 

(c)         Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and 

(d)         Disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and  

5.I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):  

(a)         All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and  

(b)         Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.  

Dated: May 07, 2021/s/ Thomas Striepe                                               

By: Thomas Striepe 

Chief Executive Officer  

EX-31.2

Exhibit 31.02

CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO RULE 13a-14

I, Thomas Striepe, certify that:

1.I have reviewed this quarterly report on Form 10-Q of Sangui Biotech International, Inc.; 

2.Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;  

3.Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;  

4.I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the small business issuer and have, for the small business issuer and have:  

(a)         Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the small business issuer, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared; 

(b)Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in  accordance with generally accepted accounting principles; 

(c)         Evaluated the effectiveness of the small business issuer’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and, 

(d)         Disclosed in this report any change in the small business issuer’s internal control over financial reporting that occurred during the small business issuer’s most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, the small business issuer’s internal control over financial reporting; and,  

5.I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the small business issuer’s auditors and the audit committee of the small business issuer’s board of directors (or persons performing the equivalent functions):  

(a)All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the small business issuer’s ability to record, process, summarize and report financial information; and,  

(b)         Any fraud, whether or not material, that involves management or other employees who have a significant role in the small business issuer’s internal control over financial reporting.  

Date: April

Dated: May 07, 2021/s/ Thomas Striepe                                               

By: Thomas Striepe 

Chief Financial Officer 

EX-32.1

Exhibit 32.01

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Sangui Biotech International, Inc. (the “Company”) on Form 10-Q for the period ending March 31, 2021 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Thomas Striepe, Chief Executive Officer and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. § 1350, as adopted pursuant to § 906 of the Sarbanes-Oxley Act of 2002, that, to the best of my knowledge and belief: 

(1)The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and 

(2)The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company. 

Dated: May 07, 2021/s/ Thomas Striepe                                               

By: Thomas Striepe 

Chief Executive Officer and 

Chief Financial Officer 

A signed original of this written statement required by Section 906, or other document authenticating, acknowledging, or otherwise adopting the signature that appears in typed form within the electronic version of this written statement has been provided to the Company and will be retained by the Company and furnished to the Securities and Exchange Commission or its staff upon request. 

XML

Document and Entity Information - shares	9 Months Ended
	Mar. 31, 2021	May 07, 2021
Details
Registrant CIK	0001104280
Fiscal Year End	--06-30
Registrant Name	SANGUI BIOTECH INTERNATIONAL INC
SEC Form	10-Q/A
Period End date	Mar. 31, 2021
Tax Identification Number (TIN)	84-1330732
Number of common stock shares outstanding		206,901,842
Filer Category	Non-accelerated Filer
Current with reporting	Yes
Interactive Data Current	Yes
Shell Company	false
Small Business	true
Emerging Growth Company	false
Amendment Description	The purpose of this Amendment No. 1 to the Periodic Report of Sangui Biotech International, Inc. (the “Company”) on Form 10-Q for the fiscal period ended March 31, 2021, filed with the Securities and Exchange Commission on May 7, 2021 (the “Form 10-Q”) is to correct the information in Part II Item 2. The Company in its Form 10-Q filing indicated that there had been no unregistered sales of its equity securities, while in fact there had been a sale of stock subsequent to the period covered by the report. This Amendment No. 1 corrects this section to reflect the recent issuance. No changes are hereby made to the registrant’s financial statements.
Document Quarterly Report	true
Entity File Number	0-21271
Entity Address, State or Province	CO
Entity Incorporation, State or Country Code	CO
Entity Address, Address Line One	Bleichenbrücke 9
Entity Address, Postal Zip Code	20354
Entity Address, City or Town	Hamburg
Entity Address, Country	DE
Country Region	49
City Area Code	40
Local Phone Number	46093120
Document Transition Report	false
Amendment Flag	true
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3

XML

Consolidated Balance Sheets - USD ($)	Mar. 31, 2021	Jun. 30, 2020
CURRENT ASSETS
Cash	$ 11,620	$ 15,282
Prepaid expenses and other assets	14,995	13,361
Tax refunds receivable	737	3,317
Accounts receivable, net	25,152	9,858
Note receivable, related party	2,066	6,878
Total Current Assets	54,570	48,696
Property and Equipment, Net	1,405	1,922
Operating lease right-of-use asset	70,349	74,710
TOTAL ASSETS	126,324	125,328
LIABILITIES
Accounts payable and accrued expenses	135,140	119,246
Accrued interest - related party	57,343	42,359
Notes payable - related party	745,962	618,568
Current portion of operating lease liability	13,743	11,312
Total Current Liabilities	952,188	791,485
Operating lease liability, net of current portion	57,390	63,721
Total Liabilities	1,009,578	855,206
STOCKHOLDERS' DEFICIT
Preferred stock, no par value; 10,000,000 shares authorized, -0- shares issued and outstanding	0	0
Common stock, no par value; 250,000,000 shares authorized 203,355,598 and 203,355,598 shares issued and 203,301,842 and 203,301,842 shares outstanding respectively	33,027,676	33,027,676
Additional paid-in capital	4,513,328	4,513,328
Treasury stock, at cost	(19,387)	(19,387)
Accumulated other comprehensive income	90,454	91,907
Accumulated deficit	(37,845,291)	(37,696,425)
Total Sangui Biotech International, Inc's stockholders' defict	(233,220)	(82,901)
Non-controlling interest	(650,034)	(646,977)
Total Stockholders' Deficit	(883,254)	(729,878)
TOTAL LIABILITIES AND STOCKHOLDERS' DEFICIT	$ 126,324	$ 125,328

XML

Consolidated Balance Sheets - Parenthetical - shares	Mar. 31, 2021	Jun. 30, 2020
Details
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Preferred Stock, Shares Outstanding	0	0
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	203,355,598	203,355,598
Common Stock, Shares, Outstanding	203,301,842	203,301,842

XML

Consolidated Statements of Operations and Comprehensive Income (Loss) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020
REVENUES
License revenues	$ 21,182	$ 9,211	$ 51,754	$ 21,176
GROSS MARGIN	21,182	9,211	51,754	21,176
OPERATING EXPENSES
Research and development	2,060	1,535	6,482	6,421
Professional fees	32,911	35,521	117,750	114,939
General and administrative	14,330	8,590	37,951	28,682
Depreciation and amortization	206	1,020	610	1,020
Total Operating Expenses	49,507	46,666	162,793	151,062
OPERATING LOSS	(28,325)	(37,455)	(111,039)	(129,886)
OTHER INCOME (EXPENSE)
Loss on out of court settlement	0	0	0	(6,714)
Gain (Loss) on foreign exchange	32,167	12,838	(27,611)	19,547
Interest expense	(4,580)	(3,667)	(13,273)	(10,357)
Total other income (expense)	27,587	9,171	(40,884)	2,476
LOSS BEFORE INCOME TAXES AND NON-CONTROLLING INTEREST	(738)	(28,284)	(151,923)	(127,410)
Provision for income taxes	0	0	0	0
NET LOSS BEFORE NON-CONTROLLING INTEREST	(738)	(28,284)	(151,923)	(127,410)
Less: Net loss attributable to non-controlling interest	648	1,588	3,057	3,982
NET LOSS ATTRIBUTABLE TO COMMON STOCKHOLDERS	(90)	(26,696)	(148,866)	(123,428)
OTHER COMPREHENSIVE LOSS
Foreign currency translation adjustments	(287)	(1,894)	(1,453)	(1,129)
COMPREHENSIVE LOSS	$ (1,025)	$ (30,178)	$ (153,376)	$ (128,539)
BASIC AND DILUTED LOSS PER SHARE	$ (0.00)	$ (0.00)	$ (0.00)	$ (0.00)
NUMBER OF SHARES OUTSTANDING	203,355,598	202,308,054	203,355,598	201,313,316

XML

Consolidated Statements of Stockholders' Equity (Deficit) - USD ($)	Common Stock	Additional Paid-in Capital	Treasury Stock	AOCI Including Portion Attributable to Noncontrolling Interest	Noncontrolling Interest	Retained Earnings	Total
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2019	$ 32,967,499	$ 4,513,328	$ (19,387)	$ 91,447	$ (641,192)	$ (37,503,684)	$ (591,989)
Shares, Outstanding, Beginning Balance at Jun. 30, 2019	199,295,503
Currency translation adjustment	$ 0	0	0	(1,129)	0	0	(1,129)
Net loss	0	0	0	0	(3,982)	(123,428)	(127,410)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2020	$ 33,023,316	4,513,328	(19,387)	90,318	(645,174)	(37,627,112)	(664,711)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	202,783,598
Proceeds from common stock issued for cash	$ 11,055	0	0	0	0	0	11,055
Common stock issued for cash	1,250,000
Common stock issued for services	$ 44,762	0	0	0	0	0	44,762
Common stock issued for services	2,238,095
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2019	$ 33,012,261	4,513,328	(19,387)	92,212	(643,586)	(37,600,416)	(645,588)
Shares, Outstanding, Beginning Balance at Dec. 31, 2019	201,533,598
Currency translation adjustment	$ 0	0	0	(1,894)	0	0	(1,894)
Net loss	0	0	0	0	(1,588)	(26,696)	(28,284)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2020	$ 33,023,316	4,513,328	(19,387)	90,318	(645,174)	(37,627,112)	(664,711)
Shares, Outstanding, Ending Balance at Mar. 31, 2020	202,783,598
Proceeds from common stock issued for cash	$ 11,055	0	0	0	0	0	11,055
Common stock issued for cash	1,250,000
Common stock issued out of court settlement	$ 0	0	0	0	0	0	0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Jun. 30, 2020	$ 33,027,676	4,513,328	(19,387)	91,907	(646,977)	(37,696,425)	(729,878)
Shares, Outstanding, Beginning Balance at Jun. 30, 2020	203,355,598
Currency translation adjustment	$ 0	0	0	(1,453)	0	0	(1,453)
Net loss	0	0	0	0	(3,057)	(148,866)	(151,923)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2021	$ 33,027,676	4,513,328	(19,387)	90,454	(650,034)	(37,845,291)	(883,254)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	203,355,598
Proceeds from common stock issued for cash							0
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Beginning Balance at Dec. 31, 2020	$ 33,027,676	4,513,328	(19,387)	90,741	(649,386)	(37,845,201)	(882,229)
Shares, Outstanding, Beginning Balance at Dec. 31, 2020	203,355,598
Currency translation adjustment	$ 0	0	0	(287)	0	0	(287)
Net loss	0	0	0	0	(648)	(90)	(738)
Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Ending Balance at Mar. 31, 2021	$ 33,027,676	$ 4,513,328	$ (19,387)	$ 90,454	$ (650,034)	$ (37,845,291)	$ (883,254)
Shares, Outstanding, Ending Balance at Mar. 31, 2021	203,355,598

XML

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$ (151,923)	$ (127,410)
Adjustments to reconcile net loss to net cash
Depreciation and amortization	610	1,020
Common stock issued for out of court settlement	0	6,714
Foreign currency exchange transactions	27,611	(19,495)
Amortization of right to use asset	(16,009)	(7,898)
Changes in operating assets and liabilities
Trade accounts receivable	(15,518)	17,261
Prepaid expenses and other current assets	(5,193)	(3,387)
Tax refunds receivable	6,660	(6,021)
Accounts payable and accrued expenses	15,604	(9,091)
Related party advances	5,665	2,054
Related party accounts payable	11,852	10,202
Operating lease liability	16,463	7,898
Net Cash Used in Operating Activities	(104,178)	(128,153)
Net Cash Provided by (Used in) Investing Activities
Purchase of equipment	0	(3,102)
Net Cash Used in Investing Activities	0	(3,102)
Net Cash Provided by (Used in) Financing Activities
Proceeds from related party note payable	101,515	105,222
Proceeds from common stock issued for cash	0	11,055
Net Cash Provided by Financing Activities	101,515	116,277
EFFECTS OF EXCHANGE RATES ON CASH	(999)	(907)
NET CHANGES IN CASH	(3,662)	(15,885)
CASH AT BEGINNING OF PERIOD	15,282	27,453
CASH AT END OF PERIOD	11,620	11,568
NON - CASH INVESTING AND FINANCING ACTIVITIES
Right-of-use operating lease assets obtained in exchange for lease liabilities	0	81,936
Common Stock issued in settlement of liability	$ 0	$ 44,762

XML

NOTE 1 - BASIS OF PRESENTATION

9 Months Ended

Mar. 31, 2021

Notes

NOTE 1 - BASIS OF PRESENTATION

NOTE 1 - BASIS OF PRESENTATION

The accompanying condensed consolidated financial statements have been prepared without audit in accordance with accounting principles generally accepted in the United States of America and rules of the Securities Exchange Commission for interim financial information. Certain information and footnote disclosures normally included in financial statements prepared in accordance with accounting principles generally accepted in the United States of America have been condensed or omitted pursuant to such rules and regulations. The unaudited condensed consolidated financial statements and notes should, therefore, be read in conjunction with the consolidated financial statements and notes thereto in the Company's Form 10-K for the year ended June 30, 2020. In the opinion of management, all adjustments (consisting of normal and recurring adjustments) considered necessary for a fair presentation, have been included. The results of operations for the three- and nine-month period ended March 31, 2021 are not necessarily indicative of the results that may be expected for the full fiscal year ending June 30, 2021.

In December 2019, COVID-19 emerged and has subsequently spread worldwide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and private entities mandating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders and advisories and quarantining of people who may have been exposed to the virus. At the present time, it is not clear how long this crisis will last and what extent it will take. The highest priority for the Company is the health of employees and business partners. The Company’s main product is affected by the restrictions currently in place around the world. The global restrictions drastically limit our sales activities. Therefore, the license revenue the Company anticipated is not, and for the foreseeable future, will not be received at the levels as planned. The Company is in close contact with its licensee who is responsible for all distribution. Both the Company and its licensee assume that the desired growth of sales will be resumed after the pandemic has been overcome and restrictions are lessened. Prior to the pandemic, the Company had essentially been financed through the sale of shares or by loans from related parties. These financing options are still available to the Company during the COVID-19 crisis.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

9 Months Ended

Mar. 31, 2021

Notes

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Nature of Business

Sangui Biotech International, Inc., (Sangui or the Company) was incorporated in Colorado in 1995 and conducts business through its 90% owned subsidiary, Sangui BioTech GmbH (Sangui GmbH) and its 99.8% owned subsidiary Sangui Know-how und Patentverwertungsgesellschaft mbH & Co. KG (Sangui KG). Sangui GmbH, which is headquartered in Hamburg, Germany, is engaged in the development of artificial oxygen carriers (external applications of hemoglobin, blood substitutes and blood additives) as well as in the development, marketing and sales of cosmetics and wound management products. Sangui KG is a limited partnership that holds the license rights under the various agreements that the Company enters into from time to time.

Consolidation

The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

Foreign Currency Translation

Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period.

Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2021 and June 30, 2020 and our unaudited consolidated statements of operations for the three- month periods ended March 31, 2021 and 2020, were calculated as follows:

as of March 31, 2021	0.851250
as of March 31, 2020	0.911235
July 1, 2020 through March 31, 2021	0.841351
July 1, 2019 through March 31, 2020	0.902936

The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other Income.

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,845,291 as of March 31, 2021. The Company incurred a net loss before non-controlling interest of $151,923 for the nine-months ended March 31, 2021 and used cash in operating activities of $104,178 during the same nine-months ended March 31, 2021. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Cash and Cash Equivalents

The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts.

Research and Development

Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred.

Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

Type of Revenue

The Company derives revenue primarily from licensing fees on sales of its wound spray product.

The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below.

The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied.

Basic and Diluted Earnings (Loss) Per Common Share

Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2021, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive.

Comprehensive Loss

Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit).

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity.

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

XML

NOTE 3 - COMMITMENTS AND CONTINGENCIES

9 Months Ended

Mar. 31, 2021

Notes

NOTE 3 - COMMITMENTS AND CONTINGENCIES

NOTE 3 - COMMITMENTS AND CONTINGENCIES

Litigation

The Company may, from time to time, be involved in various legal disputes resulting from the ordinary course of operating its business. Management is currently not able to predict the outcome of any such cases. However, management believes that the amount of ultimate liability, if any, with respect to such actions will not have a

material effect on the Company's financial position or results of operations.

At the time of reporting, no litigation is pending.

Indemnities and Guarantees

During the normal course of business, the Company has made certain indemnities and guarantees under which it may be required to make payments in relation to certain transactions. These indemnities include certain agreements with the Company's officers, under which the Company may be required to indemnify such person for liabilities arising out of their employment relationship. The duration of these indemnities and guarantees varies and, in certain cases, is indefinite. The majority of these indemnities and guarantees do not provide for any limitation of the maximum potential future payments the Company could be obligated to make. Historically, the Company has not been obligated to make significant payments for these obligations and no liabilities have been recorded for these indemnities and guarantees in the accompanying consolidated balance sheet.

Leases

The Company leases office facilities from an unrelated third party at 1,110 Euros per month, which amount includes 177 Euros for sales tax. The office lease contract began in January 2020 and expires June 2026. The Company also leases an automobile under an operating lease. The lease provides for a lease payment of 538 Euros per month that began June 2018 expired May 2020.  The company has extended the expired contract until May 2021. The monthly leasing rate is 670 Euros for the period from June 2020 to May 2021.

The following table reconciles future minimum operating lease payments to the discounted lease liability as of March 31, 2021:

Minimum Lease Payments Under Operating Leases
		Office		Automotive		Total
Year ending June 30,
2021	$	3,351	$	1,573	$	4,924
2022		13,514		-		13,514
2023		13,758		-		13,758
2024		14,005		-		14,005
Thereafter		28,772		-		28,772
Total Operating Lease Obligations	$	73,400	$	1,573	$	74,973
Less: Amount representing imputed interest	$	(3,836)	$	(4)	$	(3,840)
Present Value of minimum lease payments	$	69,564	$	1,569	$	71,133
Weighted average discount rate		2%
Weighted average remaining term		5.14	years

License Agreement

Pursuant to the contracts dated May 2, 2018 and November 11, 2018 between Sangui GmbH and Sangui KG, respectively, and a former contractor, Sangui KG grants that contractor a license fee on the license income received by Sangui for his previous services as a co-inventor. The license fee is 10% analogously to the remuneration regulation of the German Law on Employee Inventions (ArbnErfG).

XML

NOTE 4 - RELATED PARTY TRANSACTIONS

9 Months Ended

Mar. 31, 2021

Notes

NOTE 4 - RELATED PARTY TRANSACTIONS

NOTE 4 – DEBT

Notes Payable Related Parties

As of March 31, 2021, the Company had outstanding the following loans payable due to a Company Director:

Date	Loan amount in EURO	Loan amount converted into USD	Interest rate	Interest  in USD	Due
March 06, 2015	100,000	117,474	5%	34,625	June 30, 2020
December 12, 2017	25,000	29,369	2%	1,939	on demand
January 19, 2018	25,000	29,369	2%	1,878	on demand
March 13, 2018	25,000	29,369	2%	1,793	on demand
July 16, 2018	25,000	29,369	2%	1,592	on demand
September 10, 2018	25,000	29,369	2%	1,501	on demand
October 04, 2018	25,000	29,369	2%	1,463	on demand
December 27, 2018	25,000	29,369	2%	1,328	on demand
January 21, 2019	15,000	17,621	2%	772	on demand
February 26, 2019	25,000	29,369	2%	1,229	on demand
March 20, 2019	25,000	29,369	2%	1,194	on demand
April 08, 2019	20,000	23,495	2%	931	on demand
May 09, 2019	30,000	35,242	2%	1,336	on demand
June 21, 2019	30,000	35,242	2%	1,253	on demand
September 17, 2019	20,000	23,495	2%	722	on demand
October 04, 2019	20,000	23,495	2%	700	on demand
October 30, 2019	20,000	23,495	2%	667	on demand
January 08, 2020	10,000	11,747	2%	288	on demand
February 20, 2020	10,000	11,747	2%	261	on demand
March 06, 2020	15,000	17,621	2%	377	on demand
April 01, 2020	10,000	11,747	2%	234	on demand
May 05, 2020	15,000	17,621	2%	319	on demand
June 10, 2020	10,000	11,747	2%	189	on demand
July 27, 2020	10,000	11,747	2%	159	on demand
September 07, 2020	10,000	11,747	2%	132	on demand
September 21, 2020	10,000	11,747	2%	123	on demand
October 09, 2020	15,000	17,621	2%	167	on demand
December 03, 2020	10,000	11,747	2%	76	on demand
January 05, 2021	10,000	11,747	2%	55	on demand
Februay 11, 2021	10,000	11,747	2%	31	on demand
March 17, 2021	10,000	11,747	2%	9	on demand
Total	635,000	745,962		57,343

On July 27, 2020, September 07, 2020, September 21, 2020, October 09,2020, December 03,2020, January 05, 2021, February 11, 2021 and on March 17, 2021 a Company Director advanced amounts totaling 85,000 Euros ($101,515 as of March 31, 2021) to the Company. The loans are due on demand, accrue interest annually at 2% and are unsecured.    

As of March 31, 2021, all notes issued have total interest accrued of $57,343.

Interest expense for the nine-month period ended March 31, 2021 and 2020 was $13,273 and $10,357, respectively.

XML

NOTE 5 - CAPITAL STOCK

9 Months Ended

Mar. 31, 2021

Notes

NOTE 5 - CAPITAL STOCK

NOTE 5 – STOCKHOLDERS’ DEFICT

Preferred Stock – The Company is authorized to issue 10,000,000 shares of preferred stock. No preferred stock has been issued to date. The authorized preferred shares are non-voting and the Board of Directors has not designated any liquidation value or dividend rates.

Common Stock – The Company is authorized to issue 250,000,000 shares of no - par value common stock. The holders of the Company's common stock are entitled to one vote for each share held of record on all matters to be voted on by those stockholders. As of March 31, 2021, and June 30, 2020, the Company had 203,355,598 and 203,355,598 shares of common stock issued and 203,301,842 and 203,301,842 shares outstanding, respectively.

Treasury Stock - The Company holds 53,756 of its common stock as treasury stock, which is valued at cost of $19,387 as of March 31, 2021.

XML

NOTE 6 - SUBSEQUENT EVENTS

9 Months Ended

Mar. 31, 2021

Notes

NOTE 6 - SUBSEQUENT EVENTS

NOTE 6 – SUBSEQUENT EVENTS

Subsequent to March 31, 2021, the Company sold 3,600,000 shares of its common stock for approximately $58,737 in cash proceeds to one individual at price of approximately $0.0163 per share.

In accordance with ASC 855-10, the Company’s management has reviewed all material events and there are no additional material subsequent events to report.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Consolidation (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Consolidation

Consolidation

The consolidated financial statements include the accounts of Sangui BioTech International, Inc. and its subsidiaries. All significant intercompany accounts and transactions have been eliminated in consolidation.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Foreign Currency Translation

Foreign Currency Translation

Assets and liabilities of the Company's foreign operations are translated into U.S. dollars at period-end exchange rates. Net exchange gains or losses resulting from such translation are excluded from net loss but are included in comprehensive loss and accumulated in a separate component of stockholders' equity (deficit). Income and expenses are translated at average exchange rates for the period.

Exchanges rates used for the preparation of the consolidated balance sheet as of March 31, 2021 and June 30, 2020 and our unaudited consolidated statements of operations for the three- month periods ended March 31, 2021 and 2020, were calculated as follows:

as of March 31, 2021	0.851250
as of March 31, 2020	0.911235
July 1, 2020 through March 31, 2021	0.841351
July 1, 2019 through March 31, 2020	0.902936

The Company accounts for the transactions denominated in foreign currencies in the Parent Company’s books as transaction gains (losses) recognized in Other Income.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Going Concern

Going Concern

The accompanying consolidated financial statements have been prepared assuming the Company will continue as a going concern, which contemplates, among other things, the realization of assets and satisfaction of liabilities in the normal course of business. The Company has accumulated deficit of $37,845,291 as of March 31, 2021. The Company incurred a net loss before non-controlling interest of $151,923 for the nine-months ended March 31, 2021 and used cash in operating activities of $104,178 during the same nine-months ended March 31, 2021. These conditions raise substantial doubt about the Company's ability to continue as a going concern for a period of one year from issuance of the financial statements. The Company expects to continue to incur significant capital expenses in pursuing its business plan to market its products and expand its product line, while obtaining additional financing through stock offerings or other feasible financing alternatives. In order for the Company to continue its operations at its existing levels, the Company will require significant additional funds over the next twelve months. Therefore, the Company is dependent on funds raised through equity or debt offerings. Additional financing may not be available on terms favorable to the Company, or at all. If these funds are not available, the Company may not be able to execute its business plan or take advantage of business opportunities. The ability of the Company to obtain such additional financing and to achieve its operating goals is uncertain. In the event that the Company does not obtain additional capital, is not able to collect its outstanding receivables, or is not able to increase cash flow through the increase of sales, there is a substantial doubt of its being able to continue as a going concern. The accompanying condensed consolidated financial statements do not include any adjustments that might result from the outcome of this uncertainty.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Cash and Cash Equivalents (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Cash and Cash Equivalents

Cash and Cash Equivalents

The Company maintains its cash in bank accounts in Germany. Cash and cash equivalents include time deposits for which the Company has no requirements for compensating balances. The Company has not experienced any losses in its uninsured bank accounts.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Research and Development (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Research and Development

Research and Development

Research and development costs are charged to operations as they are incurred. Legal fees and other direct costs incurred in obtaining and protecting patents are expensed as incurred.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Revenue Recognition (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Revenue Recognition

Revenue Recognition

In May 2014, the FASB issued ASU No. 2014-09, Revenue from Contracts with Customers (Topic 606). The new revenue recognition standard provides a five-step analysis of transactions to determine when and how revenue is recognized. The core principle is that a company should recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services.

The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied.

Type of Revenue

The Company derives revenue primarily from licensing fees on sales of its wound spray product.

The Company recognizes revenue based on the five criteria for revenue recognition established under Topic ASC 606 set forth below.

The Company’s licenses provide a right to use and create performance obligations satisfied at a point in time. The Company recognizes revenue from the license when the performance obligation is satisfied through the transfer of the license. The Company will recognize royalty revenue a) when the licensee makes the subsequent sales or use that trigger the royalty, or (b) the performance obligation to which some or all of the sales-based or usage-based royalties has been allocated has been satisfied.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Basic and Diluted Loss per Common Share (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Basic and Diluted Loss per Common Share

Basic and Diluted Earnings (Loss) Per Common Share

Basic earnings (loss) per common share are computed by dividing income (loss) available to common stockholders by the weighted average number of common shares outstanding during the period of computation. Diluted earnings (loss) per share give effect to all potential dilutive common shares outstanding during the period of compensation. The computation of diluted earnings (loss) per share does not assume conversion, exercise or contingent exercise of securities that would have an antidilutive effect on earnings. As of March 31, 2021, the Company had no potentially dilutive securities that would affect the loss per share if they were to be dilutive.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Comprehensive Loss (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Comprehensive Loss

Comprehensive Loss

Total comprehensive loss represents the net change in stockholders' equity (deficit) during a period from sources other than transactions with stockholders and as such, includes net earnings (loss). For the Company, the components of other comprehensive loss are limited to the changes in the cumulative foreign currency translation adjustments, which is recorded as components of stockholders' equity (deficit).

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Segments of an Enterprise and Related Information (Policies)

9 Months Ended

Mar. 31, 2021

Policies

Segments of an Enterprise and Related Information

Recent Accounting Pronouncements

In February 2016, the FASB issued ASU No. 2016-02, Leases (Topic 842), ("ASC 842"). The objective of the guidance in ASC 842 is to increase transparency and comparability among organizations by recognizing lease assets and liabilities in the balance sheet and disclosing key information. ASC 842 amends previous lease guidance to require a lessee to recognize a lease liability and a right-of-use asset on the entity’s balance sheet for all leases with terms that exceed one year. ASC 842 is effective for fiscal years beginning after December 15, 2018, including interim periods within those fiscal years. ASC 842 provides that lessees (for capital and operating leases) and lessors (for sales-type, direct financing, and operating leases) must apply a modified retrospective transition approach for leases existing at, or entered into after, the beginning of the earliest comparative period presented in the financial statements. The modified retrospective approach would not require any transition accounting for leases that expired before the earliest comparative period presented. The Company elected a policy of not recording leases on its condensed balance sheets when the leases have term of 12 months or less and the Company is not reasonably certain to elect an option to purchase the leased asset. The Company recognizes payments on these leases within selling, administrative and other expenses on a straight-line basis over the lease term. The standard did not materially impact consolidated net income or liquidity.

Management does not believe that any recently issued, but not yet effective, accounting standards if currently adopted would have a material effect on the accompanying consolidated financial statements.

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation: Schedule of Foreign currency rates (Tables)

9 Months Ended

Mar. 31, 2021

Tables/Schedules

Schedule of Foreign currency rates

as of March 31, 2021	0.851250
as of March 31, 2020	0.911235
July 1, 2020 through March 31, 2021	0.841351
July 1, 2019 through March 31, 2020	0.902936

XML

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Tables)

9 Months Ended

Mar. 31, 2021

Tables/Schedules

Minimum Lease Payments Under Operating Leases

The following table reconciles future minimum operating lease payments to the discounted lease liability as of March 31, 2021:

Minimum Lease Payments Under Operating Leases
		Office		Automotive		Total
Year ending June 30,
2021	$	3,351	$	1,573	$	4,924
2022		13,514		-		13,514
2023		13,758		-		13,758
2024		14,005		-		14,005
Thereafter		28,772		-		28,772
Total Operating Lease Obligations	$	73,400	$	1,573	$	74,973
Less: Amount representing imputed interest	$	(3,836)	$	(4)	$	(3,840)
Present Value of minimum lease payments	$	69,564	$	1,569	$	71,133
Weighted average discount rate		2%
Weighted average remaining term		5.14	years

XML

NOTE 4 - RELATED PARTY TRANSACTIONS: Notes Payable Related Parties (Tables)

9 Months Ended

Mar. 31, 2021

Tables/Schedules

Notes Payable Related Parties

As of March 31, 2021, the Company had outstanding the following loans payable due to a Company Director:

Date	Loan amount in EURO	Loan amount converted into USD	Interest rate	Interest  in USD	Due
March 06, 2015	100,000	117,474	5%	34,625	June 30, 2020
December 12, 2017	25,000	29,369	2%	1,939	on demand
January 19, 2018	25,000	29,369	2%	1,878	on demand
March 13, 2018	25,000	29,369	2%	1,793	on demand
July 16, 2018	25,000	29,369	2%	1,592	on demand
September 10, 2018	25,000	29,369	2%	1,501	on demand
October 04, 2018	25,000	29,369	2%	1,463	on demand
December 27, 2018	25,000	29,369	2%	1,328	on demand
January 21, 2019	15,000	17,621	2%	772	on demand
February 26, 2019	25,000	29,369	2%	1,229	on demand
March 20, 2019	25,000	29,369	2%	1,194	on demand
April 08, 2019	20,000	23,495	2%	931	on demand
May 09, 2019	30,000	35,242	2%	1,336	on demand
June 21, 2019	30,000	35,242	2%	1,253	on demand
September 17, 2019	20,000	23,495	2%	722	on demand
October 04, 2019	20,000	23,495	2%	700	on demand
October 30, 2019	20,000	23,495	2%	667	on demand
January 08, 2020	10,000	11,747	2%	288	on demand
February 20, 2020	10,000	11,747	2%	261	on demand
March 06, 2020	15,000	17,621	2%	377	on demand
April 01, 2020	10,000	11,747	2%	234	on demand
May 05, 2020	15,000	17,621	2%	319	on demand
June 10, 2020	10,000	11,747	2%	189	on demand
July 27, 2020	10,000	11,747	2%	159	on demand
September 07, 2020	10,000	11,747	2%	132	on demand
September 21, 2020	10,000	11,747	2%	123	on demand
October 09, 2020	15,000	17,621	2%	167	on demand
December 03, 2020	10,000	11,747	2%	76	on demand
January 05, 2021	10,000	11,747	2%	55	on demand
Februay 11, 2021	10,000	11,747	2%	31	on demand
March 17, 2021	10,000	11,747	2%	9	on demand
Total	635,000	745,962		57,343

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details)	Mar. 31, 2021
Sangui BioTech GmbH
Equity Method Investment, Ownership Percentage	90.00%

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Foreign Currency Translation: Schedule of Foreign currency rates (Details)	3 Months Ended
	Mar. 31, 2021	Mar. 31, 2020
Year End Rates
Foreign Currency Exchange Rate, Translation	0.851250	0.911235
Average Period Rates
ForeignCurrencyExchangeRateTranslation	0.841351	0.902936

XML

NOTE 2 - SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES: Going Concern (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 31, 2021	Mar. 31, 2020	Jun. 30, 2020
Details
Accumulated deficit	$ 37,845,291		$ 37,845,291		$ 37,696,425
NET LOSS BEFORE NON-CONTROLLING INTEREST	$ 738	$ 28,284	151,923	$ 127,410
Net Cash Used in Operating Activities			$ 104,178	$ 128,153

XML

NOTE 3 - COMMITMENTS AND CONTINGENCIES: Minimum Lease Payments Under Operating Leases (Details)	9 Months Ended
	Mar. 31, 2021 USD ($)
2021	$ 4,924
2022	13,514
2023	13,758
2024	14,005
Thereafter	28,772
Total Operating Lease Obligations	74,973
Less: Amount representing imputed interest	(3,840)
Present Value of minimum lease payments	71,133
Office
2021	3,351
2022	13,514
2023	13,758
2024	14,005
Thereafter	28,772
Total Operating Lease Obligations	73,400
Less: Amount representing imputed interest	(3,836)
Present Value of minimum lease payments	69,564
Automobile
2021	1,573
2022	0
2023	0
2024	0
Thereafter	0
Total Operating Lease Obligations	1,573
Less: Amount representing imputed interest	(4)
Present Value of minimum lease payments	$ 1,569

XML

NOTE 4 - RELATED PARTY TRANSACTIONS: Notes Payable Related Parties (Details) - USD ($)	Mar. 31, 2021	Mar. 17, 2021	Feb. 11, 2021	Jan. 05, 2021	Dec. 03, 2020	Oct. 09, 2020	Sep. 21, 2020	Sep. 07, 2020	Jul. 27, 2020	Jun. 10, 2020	May 05, 2020	Apr. 01, 2020	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Interest rate		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Due		on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	on demand	June 30, 2020
Director
Interest rate	2.00%
Director | Euro Member Countries, Euro
Loan amount in EURO	$ 635,000	$ 10,000	$ 10,000	$ 10,000	$ 10,000	$ 15,000	$ 10,000	$ 10,000	$ 10,000	$ 10,000	$ 15,000	$ 10,000	$ 15,000	$ 10,000	$ 10,000	$ 20,000	$ 20,000	$ 20,000	$ 30,000	$ 30,000	$ 20,000	$ 25,000	$ 25,000	$ 15,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 25,000	$ 100,000
Director | United States dollar (next day) (funds code)
Loan amount converted into USD	745,962	11,747	11,747	11,747	11,747	17,621	11,747	11,747	11,747	11,747	17,621	11,747	17,621	11,747	11,747	23,495	23,495	23,495	35,242	35,242	23,495	29,369	29,369	17,621	29,369	29,369	29,369	29,369	29,369	29,369	29,369	117,474
Interest in USD	$ 57,343	$ 9	$ 31	$ 55	$ 76	$ 167	$ 123	$ 132	$ 159	$ 189	$ 319	$ 234	$ 377	$ 261	$ 288	$ 667	$ 700	$ 722	$ 1,253	$ 1,336	$ 931	$ 1,194	$ 1,229	$ 772	$ 1,328	$ 1,463	$ 1,501	$ 1,592	$ 1,793	$ 1,878	$ 1,939	$ 34,625

XML

NOTE 4 - RELATED PARTY TRANSACTIONS (Details) - USD ($)	9 Months Ended
	Mar. 31, 2021	Mar. 31, 2020	Mar. 17, 2021	Feb. 11, 2021	Jan. 05, 2021	Dec. 03, 2020	Oct. 09, 2020	Sep. 21, 2020	Sep. 07, 2020	Jul. 27, 2020	Jun. 30, 2020	Jun. 10, 2020	May 05, 2020	Apr. 01, 2020	Mar. 06, 2020	Feb. 20, 2020	Jan. 08, 2020	Oct. 30, 2019	Oct. 04, 2019	Sep. 17, 2019	Jun. 21, 2019	May 09, 2019	Apr. 08, 2019	Mar. 20, 2019	Feb. 26, 2019	Jan. 21, 2019	Dec. 27, 2018	Oct. 04, 2018	Sep. 10, 2018	Jul. 16, 2018	Mar. 13, 2018	Jan. 19, 2018	Dec. 12, 2017	Mar. 06, 2015
Accrued interest - related party	$ 57,343										$ 42,359
Interest rate			2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%		2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	2.00%	5.00%
Interest Expense	$ 13,273	$ 10,357
Director
Interest rate	2.00%
Director | Principal
Accrued interest - related party	$ 101,515
Director | Interest
Accrued interest - related party	$ 57,343

XML

NOTE 5 - CAPITAL STOCK (Details) - USD ($)	Mar. 31, 2021	Jun. 30, 2020
Details
Preferred Stock, Shares Authorized	10,000,000	10,000,000
Common Stock, Shares Authorized	250,000,000	250,000,000
Common Stock, Shares, Issued	203,355,598	203,355,598
Common Stock, Shares, Outstanding	203,301,842	203,301,842
Treasury Stock, Common, Shares	53,756
Treasury Stock, Value	$ 19,387